Alzheimer's disease drug development pipeline: 2022.

ABSTRACT:

Introduction

Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD.

Methods

We searched the governmental website clinicaltrials.gov where are all clinical trials conducted in the United States must be registered. We used artificial intelligence (AI) and machine learning (ML) approaches to ensure comprehensive detection and characterization of trials and drugs in development. We use the Common Alzheimer's Disease Research Ontology (CADRO) to classify drug targets and mechanisms of action of drugs in the pipeline.

Results

As of January 25, 2022 (i

SUBMITTER: Cummings J 

PROVIDER: S-EPMC9066743 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature